Stockscreener 앱 받기
1.38
12.66%
-0.20
시간 외 거래:
1.40
0.02
+1.45%
전일 마감가:
$1.58
열려 있는:
$1.55
하루 거래량:
196.38K
Relative Volume:
8.70
시가총액:
$30.34M
수익:
$14.79M
순이익/손실:
$-181.41M
주가수익비율:
-2.8163
EPS:
-0.49
순현금흐름:
$-68.18M
1주 성능:
-36.70%
1개월 성능:
-53.54%
6개월 성능:
-54.46%
1년 성능:
-36.99%
1일 변동 폭
$1.30
$1.6253
1주일 범위
$1.30
$2.21
52주 변동 폭
$1.30
$7.97
Celularity Inc Stock (CELU) Company Profile
명칭
Celularity Inc
전화
(908) 768-2170
주소
170 PARK AVE, FLORHAM PARK
Celularity Inc Stock (CELU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-30 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-06-22 | 개시 | H.C. Wainwright | Buy |
| 2022-04-06 | 다운그레이드 | Truist | Buy → Hold |
| 2022-01-28 | 개시 | Oppenheimer | Outperform |
| 2021-11-24 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Celularity Inc 주식(CELU)의 최신 뉴스
CELU stock touches 52-week low at $1.55 amid market fluctuations - Investing.com India
Celularity reports over $24 million in biomaterial revenue By Investing.com - Investing.com Australia
Celularity Inc. Announces Anticipated Revenues for Second and Third Quarters - Defense World
Celularity reports over $24 million in biomaterial revenue - Investing.com India
Celularity Receives Nasdaq Delisting Notice Over Filing Delay - Marketscreener.com
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel - The Manila Times
Celularity reports progress on Nasdaq compliance and product sales - Investing.com
Celularity reports progress on Nasdaq compliance and product sales By Investing.com - Investing.com Australia
Celularity Provides Corporate Update - citybiz
CELUWCelularity Inc. Warrant Latest Stock News & Market Updates - StockTitan
Celularity faces Nasdaq delisting over reporting delays - Investing.com
Celularity faces Nasdaq delisting over reporting delays By Investing.com - Investing.com UK
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal - ForexTV.com
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc. - The Manila Times
Celularity expands biomaterials range with Rebound acquisition - Investing.com India
Celularity Inc SEC 10-Q Report - TradingView
Celularity (NASDAQ:CELU) Stock Price Down 8.8%Should You Sell? - MarketBeat
Amniotic Membrane Market to Grow by USD 2.7 Billion (2024-2028) with AI Impact Boosting Trends in Ophthalmic Surgery UseTechnavio Report - The Malaysian Reserve
BTIG maintains Buy rating on Cullinan Oncology stock - Investing.com
Cullinan Oncology maintains Buy rating from H.C. Wainwright with steady price target - Investing.com India
Trend Tracker for (CLS) - Stock Traders Daily
Cullinan Therapeutics (NASDAQ:CGEM) Earns Outperform Rating from Wedbush - MarketBeat
Caesars Entertainment Inc (CZR) stock: A year of ups and downs - US Post News
In the Green: Cerus Corp. (CERS) Closes at 1.97, Up/Down -4.37 from Previous Day - The Dwinnex
Creo Medical to get £25m boost from majority sale of its European business - Business Live
Medical device company to sell stake of subsidiary to Chinese manufacturerequity value of €72m - Insider Media
Objective long/short (CGEM) Report - Stock Traders Daily
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA - Yahoo Finance
Cullinan Therapeutics Inc (CGEM)’s stock price in review: A technical analysis - US Post News
(CELC) Technical Pivots with Risk Controls - Stock Traders Daily
Creo Medical Partners with Micro-Tech for Strategic Growth - TipRanks
E Fund Management Co. Ltd. Purchases New Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
State of New Jersey Common Pension Fund D Has $3.31 Million Stock Holdings in Caesars Entertainment, Inc. (NASDAQ:CZR) - Defense World
Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com - MarketBeat
Cullinan Therapeutics commences Phase 1 trial for lupus treatment By Investing.com - Investing.com Canada
Celcuity Inc. (NASDAQ:CELC) Short Interest Update - MarketBeat
Capricor shares gain as Oppenheimer raises price target to $15 - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 5.5% - MarketBeat
Certara (NASDAQ:CERT) Shares Up 5% - MarketBeat
How Is The Market Feeling About Celestica? - Benzinga
Should You Increase Your Holdings in Certara (CERT)? - Insider Monkey
Centerra Gold shares target raised on molybdenum unit outlook - Investing.com India
Views of Wall Street’s Leading Experts on Centerra Gold Inc. - SETE News
Centuri Holdings, Inc. (NYSE:CTRI) Short Interest Update - Defense World
Caesars Entertainment Inc’s latest rating changes from various analysts - Knox Daily
Celadon Pharmaceuticals Expands Share Capital - TipRanks
Certara (NASDAQ:CERT) Sees Strong Trading Volume - MarketBeat
Is Caesars Entertainment, Inc. (NASDAQ:CZR) the Best Las Vegas Stock To Buy Now? - Yahoo Finance
Analyzing Ratios: Cullinan Therapeutics Inc (CGEM)’s Financial Story Unveiled - The Dwinnex
Cullinan Oncology's stock gets buy rating after trial data - Investing.com
Does Cerus Corp. (CERS) offer a good opportunity for investors? - SETE News
Celularity Inc (CELU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
0.26%
자본화:
|
볼륨(24시간):